Pathstone Holdings LLC Has $14.88 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Pathstone Holdings LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 560,936 shares of the biopharmaceutical company's stock after selling 85,935 shares during the period. Pathstone Holdings LLC's holdings in Pfizer were worth $14,882,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Fiduciary Alliance LLC lifted its stake in shares of Pfizer by 15.5% in the 4th quarter. Fiduciary Alliance LLC now owns 9,803 shares of the biopharmaceutical company's stock valued at $260,000 after acquiring an additional 1,319 shares during the last quarter. Rosenberg Matthew Hamilton grew its stake in shares of Pfizer by 59.9% in the 4th quarter. Rosenberg Matthew Hamilton now owns 2,029 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 760 shares during the last quarter. Mayfair Advisory Group LLC lifted its position in Pfizer by 4.7% in the 4th quarter. Mayfair Advisory Group LLC now owns 10,758 shares of the biopharmaceutical company's stock valued at $285,000 after acquiring an additional 479 shares in the last quarter. 626 Financial LLC lifted its position in Pfizer by 15.4% in the 4th quarter. 626 Financial LLC now owns 48,849 shares of the biopharmaceutical company's stock valued at $1,296,000 after acquiring an additional 6,514 shares in the last quarter. Finally, Accurate Wealth Management LLC lifted its holdings in shares of Pfizer by 17.6% during the 4th quarter. Accurate Wealth Management LLC now owns 35,736 shares of the biopharmaceutical company's stock valued at $955,000 after buying an additional 5,360 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Up 1.0%

NYSE PFE traded up $0.23 during trading hours on Friday, reaching $22.83. 37,727,922 shares of the company traded hands, compared to its average volume of 40,866,554. The company has a 50 day moving average of $23.65 and a two-hundred day moving average of $25.36. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market capitalization of $129.77 billion, a PE ratio of 16.19, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter last year, the company earned $0.82 EPS. Pfizer's quarterly revenue was down 7.8% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.